Indeed, in monocytes stimulated with one of the cytokines present in the TME, TNF-α, ITF3756 is not only able to reduce one of the main targets of cancer immunotherapy, PD-L1, but it is also able to drive monocytes towards a less immunosuppressive phenotype, with reduced expression of M2 phenotypic markers, and with an increased glycolytic metabolism and with an improved capacity of inducing T cells proliferation in vitro. The gene discussed is TNF; the disease is cancer.